The real missing data problem

A future piece of research, pending planning, funding etc. is to investigate the true extent of the “missing data problem” for recently-approved pharmaceuticals, correlating the publicly registered studies involving each medicine with the published results and highlighting any gaps, on a per-compound and per-sponsor basis.

While the ideal situation would be for the medical community to have complete access to all data from all studies on all approved compounds, restricting the survey to a limited number of “high profile” medicines would give a better insight into current publication practices.